{
    "850f305d-14db-4c75-b547-79470a557ea3-553531": {
        "articles": {
            "resultCount": 20,
            "results": [
                {
                    "body": "A prototype vaccine for dengue that two years ago yielded lukewarm results has proved more effective after wider trials and is a potential arm against the disease, researchers said Friday.\n Devised by the French pharmaceutical giant Sanofi Pasteur, the so-called CYD-TDV vaccine provided only 30 percent protection against the dangerous fever when first tested among children in Thailand.\n Widened to trials in four other Asian countries, where disease conditions vary greatly, the vaccine's protection has been shown to be significantly higher, at 56.5 percent overall, the scientists said.\n The result falls short of the benchmark set by classic vaccines such as those for polio and measles, which can be more than 99 percent effective.\n One reason for this is that CYD-TDV performed poorly against one of the four strains of dengue virus, the investigators reported in The Lancet.\n These strains, or serotypes, circulate simultaneously, which means a vaccine should ideally protect against all of them.\n Even so, the prototype was safe and well tolerated and its shield, if only partial, means it should be enlisted in the fight against dengue, they argued.\n \"Our results suggest that vaccination with CYD-TDV can reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalisations,\" said Maria Rosario Capeding from the Philippines' Research Institute for Tropical Medicine.\n \"This candidate vaccine has the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\" \"\nDengue is a potentially fatal fever, caused by a virus transmitted by a mosquito when it takes its blood meal, and is especially dangerous for children.\n The virus infects around 390 million people each year, of whom about 96 million fall sick, according to UN estimates.\n It was once considered a disease of the tropics that was endemic in only nine countries.\n But globalisation, climate change and jet travel are helping it to move into more temperate zones.\n According to the World Health Organization (WHO) cases of dengue have risen 30 fold over the last 50 years, and more than half of the world's population are at risk of the disease.\n - Wider trials -\nThe CYD-TDV vaccine was tested as a so-called Phase IIb trial among just over 4,000 children in rural Thailand, the results of which were reported in September 2012.\n The new figures are those of a Phase III trial -- normally the final step in the process to test new drugs for safety and efficiency -- carried out in Indonesia, Malaysia, the Philippines and Vietnam, as well as in Thailand.\n More than 10,000 children aged two to 14 years were enrolled.  They were randomly assigned to receive three injections of the vaccine or a placebo over 12 months, and were followed for up to two years.\n During this period a total of 150 dengue cases occurred, a majority of them in the placebo group, demonstrating an overall effectiveness of 56.5 percent.\n But the protection varied according to the serotype -- more than 75 percent against virus types 3 and 4; 50 percent against type 1; but only 35 percent against type 2.\n On the plus side, those who had received the vaccine were also far less likely to fall ill with a severe form of the disease, dengue haemorrhagic fever, which leads to half a million hospitalisations each year.\n In a commentary, Annelies Wilder-Smith, a professor at Singapore's Nanyang Technological University, said a vaccine that halved annual cases of dengue \"would present a significant public health benefit\" but was not a magic bullet.\n \"For the moment, the CYD-TDV vaccine is the best we have; however, with 56 percent efficacy it will never be a single solution,\" Wilder-Smith said.\n Other strategies, including better approaches to tackling mosquitoes that cause the problem, would also have to be part of the campaign, she said.\n The children in the trial are being followed up for another four years to see whether the vaccine's promise still holds up.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14812580",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7564,
                    "source": {
                        "title": "Raw Story",
                        "uri": "www.rawstory.com"
                    },
                    "time": "10:56:00",
                    "title": "Test vaccine for dengue fever seen as promising",
                    "uri": "196265236",
                    "url": "http://www.rawstory.com/rs/2014/07/11/test-vaccine-for-dengue-fever-seen-as-promising/",
                    "wgt": 1
                },
                {
                    "body": "The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.\n Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection.  WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with over half of the world's population at risk of the disease.\n There is no licensed vaccine available to treat or prevent dengue fever, and efforts to develop one have been complicated by the fact that dengue is caused by four distinct dengue viruses, and a vaccine must target all four serotypes (DENV 1-4).\n This phase 3 trial took place in dengue-endemic areas across five countries in Asia, a region that accounts for over 70% of the global dengue burden.  The study involved 10 275 healthy children aged 2 to 14 years who were randomly assigned to receive three injections of the CYD-TDV vaccine (6851) or a placebo (3424) at 0, 6, and 12 months, and followed for up to 2 years.\n The researchers recorded 250 dengue cases more than 28 days after the third injection -- 117 in the vaccine group and 133 in the placebo group, demonstrating an overall protective efficacy of 56.5%.\n The vaccine also showed 88.5% efficacy after 3 doses against severe disease (dengue haemorrhagic fever) which leads to hospitalisation for over half a million people (mostly children) every year, and 67% against dengue-associated hospitalisation.\n The researchers found that the vaccine gave low protection (35%) against DENV 2, but more than 75% protection against DENV 3 and 4, and 50% against DENV 1.\n The vaccine was generally well tolerated.  A total of 647 serious adverse events were reported, 402 (62%) in the vaccine group and 245 (38%) in the placebo group.\n According to lead author Dr Maria Rosario Capeding from the Research Institute for Tropical Medicine in the Philippines, \"Our results suggest that vaccination with CYD-TDV can reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalisations.  This candidate vaccine has the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\" \"*\nWriting in a linked Comment, Professor Annelies Wilder-Smith from Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore says, \"Perhaps the most interesting finding of this trial was that efficacy after at least one dose was almost as high as that after three doses...B Because three doses 6 months apart is an inconvenient and costly immunisation schedule for scale up in national programmes, the question of whether sufficient efficacy can be achieved with a lower number of doses deserves further assessment.\" \"\nShe adds, \"With an estimated 96 million clinically apparent dengue infections annually, a reduction by half would present a significant public health benefit that would support dengue vaccine introduction....Whether the armamentarium of alternative vaccine candidates presently in the pipeline (including inactivated, live attenuated, chimeric, recombinant, subunit and DNA vaccines) will improve efficacy beyond 56% remains to be established.  For the moment, the CYD-TDV vaccine is the best we have; however, with 56% efficacy it will never be a single solution.  Continued support for the development of other novel strategies including drugs, improved case management, insecticides, and new approaches to vector control, is needed before effective dengue control becomes a credible prospect.\" \"",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14763388",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.748,
                    "source": {
                        "title": "www.sciencecodex.com",
                        "uri": "www.sciencecodex.com"
                    },
                    "time": "02:18:00",
                    "title": "World's most advanced dengue vaccine shows promise in phase 3 trial",
                    "uri": "196188235",
                    "url": "http://www.sciencecodex.com/the_lancet_worlds_most_advanced_dengue_vaccine_candidate_shows_promise_in_phase_3_trial-137356",
                    "wgt": 1
                },
                {
                    "body": "THURSDAY, July 10, 2014 (HealthDay News) -- A potential vaccine to protect children from the worldwide scourge of dengue fever was somewhat successful in a trial among Asian children.\n While the vaccine only prevented dengue fever in 56 percent of the 10,000 kids who got the full series of three shots, it protected more than 88 percent of them from severe disease.  In the worst-case scenarios, dengue fever can lead to hospitalization, and sometimes death.\n \"This vaccine has already proven to be safe,\" said Tyler Sharp, an epidemiologist in the dengue branch of the U.S. Centers for Disease Control and Prevention, who had no role in the trial.  \"We know that this vaccine does not lead to a risk of developing severe dengue -- that is a huge step forward.\" \"\nHowever, \"the 56 percent is not as high as we would like to see it.  It's still a big step forward, but we have a way to go before we get a vaccine that is both safe and as efficacious as we would need it to be,\" Sharp added.\n Of the 400 million people infected worldwide every year, about half have mild symptoms such as fever and body pain that goes away in a couple of days, Sharp said.  But the other half have intense pain, severe headaches and high fever, and some may have minor bleeding under the skin, or from the gums or nose, he added.  There is no treatment for dengue.\n In the United States, dengue is endemic in Puerto Rico, the U.S. Virgin Islands and the U.S. territories in the Pacific Ocean, Sharp said.  Although isolated cases of the mosquito-borne disease have cropped up in Florida and Texas in recent years, Sharp said he did not expect the disease to gain a foothold in the continental United States.\n Dr. Annelies Wilder-Smith, a professor of infectious diseases research at the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore, stressed that a more effective vaccine is needed.\n \"Of course, our desire is to have a vaccine efficacy of above 90 percent,\" she noted.\n Wilder-Smith, who authored an accompanying journal editorial, noted that other dengue vaccines are being tested, but it will take several years before those vaccines reach phase 3 trials.\n \"For the time being, this is the best and the only one we have,\" she said of the current vaccine, known as CYD-TDV.\n The report, from scientists at the Research Institute for Tropical Medicine in the Philippines, was published online July 11 in The Lancet.\n Dr. Marcelo Laufer, an infectious diseases specialist at Miami Children's Hospital, said he was \"not impressed\" by the efficacy of the vaccine.\n Laufer also noted that the vaccine needs to be tested in other areas, particularly in Latin America, and that patients need to be followed for at least five years.\n \"I am curious to see how the vaccine would work in different populations,\" he said.\n The trial, funded by vaccine maker Sanofi Pasteur, focused on children aged 2 to 14.  They were randomly assigned to receive three injections of the CYD-TDV vaccine or a placebo vaccine.\n After the first vaccination, the second was given six months later and the third six months after that.  The children were followed for up to two years.\n More than 28 days after the third vaccination, 117 children who received the vaccine developed dengue, compared with 133 who were given placebo.  That works out to a vaccine effectiveness rate of 56.5 percent, the researchers noted.\n In addition, after three doses, the vaccine was 88.5 percent effective against severe disease, which often leads to hospitalization for over 500,000 people -- mostly children -- every year.\n \"One of the difficulties in making a dengue vaccine is that you have to cover for four different viruses at the same time,\" Sharp explained.  \"If you are not able to do that, you risk increasing the chances of developing severe dengue.\" \"\nThe vaccine wasn't equally effective against all four dengue viruses.  It was only 35 percent effective against type 2, more than 75 percent effective against types 3 and 4, and 50 percent effective against type 1.\n The vaccine was well tolerated, the researchers reported.  A total of 402 serious adverse events were reported in the vaccine group and 245 were reported in the placebo group.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14898390",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7463,
                    "source": {
                        "title": "Medline Plus",
                        "uri": "www.nlm.nih.gov"
                    },
                    "time": "19:19:00",
                    "title": "Dengue Fever Vaccine Shows Some Promise in Trial",
                    "uri": "196412792",
                    "url": "http://www.nlm.nih.gov/medlineplus/news/fullstory_147253.html",
                    "wgt": 1
                },
                {
                    "body": "Devised by the French pharmaceutical giant Sanofi Pasteur, the so-called CYD-TDV vaccine provided only 30 percent protection against the dangerous fever when first tested among children in Thailand.\n Widened to trials in four other Asian countries, where disease conditions vary greatly, the vaccine's protection has been shown to be significantly higher, at 56.5 percent overall, the scientists said.\n The result falls short of the benchmark set by classic vaccines such as those for polio and measles, which can be more than 99 percent effective.\n One reason for this is that CYD-TDV performed poorly against one of the four strains of dengue virus, the investigators reported in The Lancet.\n These strains, or serotypes, circulate simultaneously, which means a vaccine should ideally protect against all of them.\n Even so, the prototype was safe and well tolerated and its shield, if only partial, means it should be enlisted in the fight against dengue, they argued.\n \"Our results suggest that vaccination with CYD-TDV can reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalizations,\" said Maria Rosario Capeding from the Philippines' Research Institute for Tropical Medicine.\n \"This candidate vaccine has the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\" \"\nDengue is a potentially fatal fever, caused by a virus transmitted by a mosquito when it takes its blood meal, and is especially dangerous for children.\n The virus infects around 390 million people each year, of whom about 96 million fall sick, according to UN estimates.\n It was once considered a disease of the tropics that was endemic in only nine countries.\n But globalization, climate change and jet travel are helping it to move into more temperate zones.\n The World Health Organization (WHO) suggests that cases of dengue have risen 30 fold over the last 50 years, and more than half of the world's population are at risk of the disease.\n - Wider trials -\nThe CYD-TDV vaccine was tested as a so-called Phase IIb trial among just over 4,000 children in rural Thailand, the results of which were reported in September 2012.\n The new figures are those of a Phase III trial -- normally the final step in the process to test new drugs for safety and efficiency -- carried out in Indonesia, Malaysia, the Philippines and Vietnam, as well as in Thailand.\n More than 10,000 children aged two to 14 years were enrolled.  They were randomly assigned to receive three injections of the vaccine or a placebo over 12 months, and were followed for up to two years.\n During this period a total of 150 dengue cases occurred, a majority of them in the placebo group, demonstrating an overall effectiveness of 56.5 percent.\n But the protection varied according to the serotype -- more than 75 percent against virus types 3 and 4; 50 percent against type 1; but only 35 percent against type 2.\n On the plus side, those who had received the vaccine were also far less likely to fall ill with a severe form of the disease, dengue haemorrhagic fever, which leads to half a million hospitalizations each year.\n In a commentary, Annelies Wilder-Smith, a professor at Singapore's Nanyang Technological University, said a vaccine that halved annual cases of dengue \"would present a significant public health benefit\" but was not a magic bullet.\n \"For the moment, the CYD-TDV vaccine is the best we have; however, with 56 percent efficacy it will never be a single solution,\" Wilder-Smith said.\n Other strategies, including better approaches to tackling mosquitoes that cause the problem, would also have to be part of the campaign, she said.\n The children in the trial are being followed up for another four years to see whether the vaccine's promise still holds up.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14826069",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7405,
                    "source": {
                        "title": "Medindia",
                        "uri": "www.medindia.net"
                    },
                    "time": "12:23:00",
                    "title": "Promising Results for Test Vaccine for Dengue",
                    "uri": "196292249",
                    "url": "http://www.medindia.net/news/promising-results-for-test-vaccine-for-dengue-138590-1.htm",
                    "wgt": 1
                },
                {
                    "body": "Dengue fever, also known as breakbone fever, is a viral disease that is spread through infected mosquitoes.  According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 400 million people get infected every year.  In order to reduce this number, researchers have been testing a new dengue fever vaccine in Asian children.  So far, the trial is promising.\n The trial recruited 10,275 children between the ages of two and 14 from five countries throughout Asia.  The children were randomly assigned to the vaccine group or the placebo group.  Children in the vaccine group received three shots, six months apart from one another.  The researchers monitored the children for up to two years.\n 28 days after the last vaccine, the researchers reported that 117 vaccinated children developed dengue fever.  The number from the placebo group was 133.  The vaccine's effectiveness rate in preventing dengue fever was 56.5 percent.  The team calculated that the vaccine's effectiveness rate in protecting children from acquiring the severe version of the disease was higher, at 88.5 percent.\n \"This vaccine has already proven to be safe,\" said Tyler Sharp, an epidemiologist in the dengue branch of the CDC, who was not involved with the trial, reported by Philly.  \"We know that this vaccine does not lead to a risk of developing severe dengue -- that is a huge step forward.  [However] the 56 percent is not as high as we would like to see it.  It's still a big step forward, but we have a way to go before we get a vaccine that is both safe and as efficacious as we would need it to be.\" \"\nThe researchers counted a total of 402 adverse side effects associated with the vaccine group.  The placebo group had a total of 245 adverse events.  The researchers noted that the vaccine did not protect young children as effectively as they would have hoped.  Instead, the team believes that the vaccine works better as an immune booster for children who had already been exposed to the virus.\n \"In view of the high disease burden in endemic countries... this vaccine candidate, despite moderate overall efficacy, could have a substantial effect on public health,\" the researchers concluded according to Reuters.\n The trial was headed by Maria Rosario Capeding from the Research Institute for Tropical Medicine in the Philippines and funded by the vaccine manufacturer, Sanofi.  The study, \"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial,\" was published in The Lancet.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14860519",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7344,
                    "source": {
                        "title": "Counsel & Heal",
                        "uri": "www.counselheal.com"
                    },
                    "time": "12:02:00",
                    "title": "Dengue Fever Vaccine is Promising in Early Trial",
                    "uri": "196354399",
                    "url": "http://www.counselheal.com/articles/10435/20140711/dengue-fever-vaccine-is-promising-in-early-trial.htm",
                    "wgt": 1
                },
                {
                    "body": "AsianScientist (Jul 11, 2014) - Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi, have published the full results of the highly anticipated Phase III trial for their candidate dengue vaccine in The Lancet.\n The tetravalent live attenuated vaccine, CYD-TDV, showed a modest efficacy against symptomatic dengue of 56 percent, a nonetheless marked improvement over an earlier Phase II trial conducted in Thailand which showed only 33 percent efficiency.  Importantly, the vaccine showed an 89 percent reduction in dengue hemorrhagic fever, a life-threatening complication of the disease.\n Dengue incidence has increased 30 fold over the past 50 years in Asia, a region which bears 75 percent of the global burden of dengue.  A recent study by Brandeis University researchers showed that the estimated economic burden of dengue in Southeast Asia alone is close to US$1 billion each year.  There is currently no specific treatment for the disease, and the development of a vaccine has been complicated by the concurrent circulation of four different dengue strains.\n Sanofi Pasteur's randomized multicenter trial involved 10,275 children between the ages of 2 and 14 years from five dengue endemic countries: Indonesia, Malaysia, the Philippines, Thailand and Vietnam.  The children received three injections of the vaccine at six monthly intervals and were followed for the next 25 months.\n The vaccine was shown to be 75 percent effective against dengue serotypes 3 and 4, 50 percent against serotype 1, but only 35 percent effective against serotype 2, resulting in an overall efficiency against all four strains of 56 percent.\n Furthermore, the vaccine was shown to be much less effective in younger children (aged 2-5 years), the group most affected by the disease.  The vaccine was also shown to be less effective in children who had never been exposed to the virus before, suggesting that the vaccine acts in such a way as to boost and broaden the existing immune response rather than generate new protective immunity.\n Despite the incomplete and strain-specific protection, the vaccine was nonetheless able to reduce dengue hemorrhagic fever by 89 percent, thereby making a profound impact on hospital admissions and dengue-related deaths.  It also demonstrated a good safety profile, with similar rates of serious adverse events in the vaccine and control groups.\n As the only successful dengue vaccine to have made it to Phase III clinical trials, the Sanofi Pasteur CYD-TDV vaccine could play an important role in the public health response against dengue, despite its moderate efficacy.  Having invested over 20 years of research and approximately US$1.77 billion on the dengue vaccine, Sanofi Pasteur is keen to bring the vaccine to market, and has already built a production site in Lyon capable of producing 100 million doses a year.\n Other pharmaceutical companies currently developing dengue vaccines include Takeda, which acquired Inviragen in 2013 and is in the midst of Phase II trials for the vaccine DENVax, and Merck, currently in Phase I trials for a dengue vaccine acquired during the 2010 purchase of Hawaii Biotech's vaccine research unit.\n The article can be found at: Capeding et al.  (2014) Clinical Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children in Asia: a Phase 3, Randomised, Observer-masked, Placebo-controlled Trial.\n -- -\nCopyright: Asian Scientist Magazine; Photo: Antonia Esponda/Flickr/CC.\n Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14810445",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7319,
                    "source": {
                        "title": "Asian Scientist Magazine |  Science, Technology and Medicine News Updates From Asia",
                        "uri": "www.asianscientist.com"
                    },
                    "time": "06:43:00",
                    "title": "Sanofi's Dengue Vaccine Promising But Offers Incomplete Protection",
                    "uri": "196264251",
                    "url": "http://www.asianscientist.com/in-the-lab/sanofi-dengue-vaccine-promising-offers-incomplete-protection-2014/",
                    "wgt": 1
                },
                {
                    "body": "Sanofi is edging close to the fruition of a 20-year effort to develop the first effective vaccine against dengue fever, which hospitalises half a million people a year.\n Data from the first phase III trial of the vaccine have now been published in The Lancet and indicate that a three-dose course of the vaccine given to children aged two to 14 had an overall efficacy of 57 per cent against symptomatic dengue.\n Moreover, Sanofi's shot reduced the risk of a severe form of the disease known as dengue haemorrhagic fever by almost 89 per cent and cut the risk of hospitalisation by two thirds, according to the trial in five Asian countries.  The results also indicate the vaccine is safe, said Sanofi, which hopes to make it available next year.\n Around half the world's population is at risk of developing dengue fever, and while the burden is most felt in Asia and Latin America, its incidence is on the increase in many other areas of the world as travellers bring the virus back with them from trips abroad.\n For example, Public Health England (PHE) recently reported a 58 per cent increase in cases to 541 last year, mainly contracted during visits to countries such as India and Thailand where the disease is endemic.\n Dengue is spread by mosquitoes and symptoms include fever, a hammering headache, flu-like symptoms, bone, muscle and joint pain, rash and nausea and vomiting.\n Symptoms generally clear within two weeks in fit and healthy people, but it can take months to recover and a minority of patients go on to develop haemorrhagic fever that can lead to organ damage.  It kills around 22,000 people a year, according to the World Health Organization (WHO), and puts huge strain on hospitals and healthcare systems during outbreaks.\n \"The threat of severe dengue disease creates fear in the community,\" said the trial's principal investigator Dr Maria Rosario Capeding of the Research Institute for Tropical Medicine in the Philippines, who suggested the vaccine's impact on haemorrhagic fever is particularly exciting from a public health perspective.\n \"A vaccine that is able to avoid the personal suffering and reduce this significant health burden would change the lives of millions,\" she noted.\n Sanofi has a second trial of the vaccine ongoing in Latin America that is due to report data in the third quarter of this year.  If those results are similarly positive, analysts have predicted the vaccine will be rolled out quickly and could generate peak sales of around $1.4bn a year, making it one of the brightest prospects in Sanofi's pipeline.\n Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.  The vaccine - called DENvax - is in phase II testing.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14808241",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.716,
                    "source": {
                        "title": "www.pmlive.com",
                        "uri": "www.pmlive.com"
                    },
                    "time": "10:23:00",
                    "title": "Sanofi's dengue vaccine could debut in 2015",
                    "uri": "196259256",
                    "url": "http://www.pmlive.com/pharma_news/sanofis_dengue_vaccine_could_debut_in_2015_585403",
                    "wgt": 1
                },
                {
                    "body": "The latest trial results of what has been dubbed the world's first vaccine against dengue show more than 50% of children who received the vaccine are protected against the disease.\n Researchers treated 6,000 children aged 2-14 across the five countries in Asia: Indonesia, Malaysia, Thailand, the Philippines and Vietnam.  The results showed that the vaccine provided protection against the virus to 56 per cent of the children at the end of two years.  The shot proved most effective for children with certain subtypes of the virus and those who had been exposed to it before, and had even stronger impact on severe forms of the disease.\n \"Given that dengue is a major public health problem in most Asian countries the findings have the potential to have a huge impact on public health,\" said lead author Dr Maria Rosario Capeding, from the Research Institute for Tropical Medicine in the Philippines.  \"A 56% reduction, though moderate, can translate into a huge benefit for countries plagued by the disease.\" \"\nThe vaccine was developed by French pharmaceutical company Sanofi which plans to apply for approval once the results of its second trial across Latin America and the Caribbean have been analysed.  The shot's efficacy improved in the latest study to 56 per cent compared to 33 per cent in 2012 early trial.\n According to the World Health Organization (WHO) cases of dengue have risen 30 fold over the last 50 years.  The disease affects about 100 million people every year, mostly in Asia, Africa and Latin America, and there are currently no treatments to prevent dengue fever.  The virus is borne by mosquitoes, and the most common symptoms of the disease include fever, severe joint pain, headaches and bleeding.",
                    "date": "2014-07-12",
                    "eventUri": "970955",
                    "id": "15017285",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.7142,
                    "source": {
                        "title": "yottafire.com",
                        "uri": "yottafire.com"
                    },
                    "time": "11:59:00",
                    "title": "Sanofi's Vaccine Considered A Potential Arm Against Dengue",
                    "uri": "196633059",
                    "url": "http://yottafire.com/2014/07/sanofis-vaccine-considered-a-potential-arm-against-dengue/",
                    "wgt": 1
                },
                {
                    "body": "THURSDAY, July 10, 2014 (HealthDay News) -- A potential vaccine to protect children from the worldwide scourge of dengue fever was somewhat successful in a trial among Asian children.\n While the vaccine only prevented dengue fever in 56 percent of the 10,000 kids who got the full series of three shots, it protected more than 88 percent of them from severe disease.  In the worst-case scenarios, dengue fever can lead to hospitalization, and sometimes death.\n \"This vaccine has already proven to be safe,\" said Tyler Sharp, an epidemiologist in the dengue branch of the U.S. Centers for Disease Control and Prevention, who had no role in the trial.  \"We know that this vaccine does not lead to a risk of developing severe dengue -- that is a huge step forward.\" \"\nHowever, \"the 56 percent is not as high as we would like to see it.  It's still a big step forward, but we have a way to go before we get a vaccine that is both safe and as efficacious as we would need it to be,\" Sharp added.\n Of the 400 million people infected worldwide every year, about half have mild symptoms such as fever and body pain that goes away in a couple of days, Sharp said.  But the other half have intense pain, severe headaches and high fever, and some may have minor bleeding under the skin, or from the gums or nose, he added.  There is no treatment for dengue.\n In the United States, dengue is endemic in Puerto Rico, the U.S. Virgin Islands and the U.S. territories in the Pacific Ocean, Sharp said.  Although isolated cases of the mosquito-borne disease have cropped up in Florida and Texas in recent years, Sharp said he did not expect the disease to gain a foothold in the continental United States.\n Dr. Annelies Wilder-Smith, a professor of infectious diseases research at the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore, stressed that a more effective vaccine is needed.\n \"Of course, our desire is to have a vaccine efficacy of above 90 percent,\" she noted.\n Wilder-Smith, who authored an accompanying journal editorial, noted that other dengue vaccines are being tested, but it will take several years before those vaccines reach phase 3 trials.\n \"For the time being, this is the best and the only one we have,\" she said of the current vaccine, known as CYD-TDV.\n The report, from scientists at the Research Institute for Tropical Medicine in the Philippines, was published online July 11 in The Lancet.\n Dr. Marcelo Laufer, an infectious diseases specialist at Miami Children's Hospital, said he was \"not impressed\" by the efficacy of the vaccine.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14883598",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6992,
                    "source": {
                        "title": "WebMD",
                        "uri": "www.webmd.com"
                    },
                    "time": "18:03:00",
                    "title": "Dengue Fever Vaccine Shows Some Promise in Trial",
                    "uri": "196392343",
                    "url": "http://www.webmd.com/news/20140711/dengue-fever-vaccine?src=RSS_PUBLIC",
                    "wgt": 1
                },
                {
                    "body": "Dengue, the world's fastest-growing tropical disease, may have met a fierce competitor in a promising dengue vaccine from Sanofi, based in France.\n A study, funded by Sanofi, included more than 10,000 healthy children ranging in age from 2 to 14.  The trial spanned five Asian countries that have been ravaged by the disease.  The countries involved make up two-thirds of dengue fever's global burden.\n The disease is caused by four related viruses and is transmitted to humans by infected mosquitoes.  A more serious form of the disease is dengue hemorrhagic fever (DHF), which, if not properly treated, can be fatal.  However, appropriate medical management can reduce the mortality rate to less than 1 percent.\n The vaccine offers hope to the countries where dengue is well-known.  The World Health Organization (WHO) estimates that up to 50 million infections occur annually.  Of those, 500,000 are cases of DHF and 22,000 are fatal with deaths occurring mainly among children.  The Lancet medical journal published the full findings of the study online Friday.  The study results show that the vaccine was safe and helped to reduce serious cases of hemorrhagic fever by almost 90 percent.\n Unfortunately, the dengue vaccine does not offer good protection to young children, who are most at risk for the disease.  The vaccine was also inefficient in handling one of the four strains of the disease.  These results show that the new vaccine may be most useful as an immune booster for patients with previous exposure to dengue, which means travelers may not find it helpful as they typically have not been exposed to the disease.\n Still, the vaccine is promising for those who live in affected regions and the results \"take us closer to our ambition to bring the first vaccine against dengue to the world,\" said John Shiver, R&D chief at Sanofi Pasteur.  He added that \"after more than 20 years of commitment in collaboration with the scientific community, we are on course to make dengue the next vaccine-preventable disease.\" \"\nIn the last 20 years, Sanofi invested more than 1.3 billion euros ($1.77 billion) to develop the vaccine.  The company also built a dedicated factory in southern France near Lyon.  The factory is able to produce 100 million doses per year of the vaccine.",
                    "date": "2014-07-12",
                    "eventUri": "970955",
                    "id": "15017286",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6974,
                    "source": {
                        "title": "Mod Vive",
                        "uri": "www.modvive.com"
                    },
                    "time": "10:40:00",
                    "title": "Sanofi's dengue vaccine shows promise despite limitations",
                    "uri": "196633058",
                    "url": "http://www.modvive.com/2014/07/12/sanofis-dengue-vaccine-shows-promise-despite-limitations/",
                    "wgt": 1
                },
                {
                    "body": "The vaccine also provides protection against dengue-associated hospitalisation.\n KUALA LUMPUR: The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown 88.5% efficacy after three doses against dengue haemorrhagic fever, according to a new research published in The Lancet.\n Once administered CYD-TDV also provides 67% protection against dengue-associated hospitalisation.\n Researchers found that the vaccine gave low protection (35%) against the DENV 2 strain but more than 75% protection against the DENV 3 and 4 and 50% against the DENV 1.\n Overall the vaccine has shown moderate protection (56%) against the disease in Asian children.\n This phase 3 trial took place in dengue-endemic areas across five countries in Asia, a region that accounts for over 70% of the global dengue burden.\n The study involved 10,275 healthy children aged two to 14 years who were randomly assigned to receive three injections of the CYD-TDV vaccine (6,851) or a placebo (3,424) at zero, six, and 12 months which was followed for up to two years.\n The researchers recorded 250 dengue cases more than 28 days after the third injection-117 in the vaccine group and 133 in the placebo group demonstrating an overall protective efficacy of 56.5%.\n Lead author Maria Rosario Capeding from the Research Institute for Tropical Medicine in the Philippines said, \"Our results suggest that vaccination with CYD-TDV can reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalisations.\n \"This candidate vaccine has the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\" \"\nAnnelies Wilder-Smith from Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore said, \"Perhaps the most interesting finding was that efficacy after at least one dose was almost as high as that after three doses.\n \"Because three doses six months apart is an inconvenient and costly immunisation schedule to scale up in national programmes, the question of whether sufficient efficacy can be achieved with a lower number of doses deserves further assessment.\" \"",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14787950",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6882,
                    "source": {
                        "title": "Free Malaysia Today",
                        "uri": "www.freemalaysiatoday.com"
                    },
                    "time": "04:08:00",
                    "title": "Developing dengue vaccine shows 88% success",
                    "uri": "196221927",
                    "url": "http://www.freemalaysiatoday.com/category/nation/2014/07/11/developing-dengue-vaccine-shows-88-success/",
                    "wgt": 1
                },
                {
                    "body": "Washington: The first dengue vaccine candidate (CYD-TDV) has shown moderate protection (56 percent) against the disease in Asian children in phase 3 clinical testing, according to a new research.\n The vaccine also showed 88.5 percent efficacy after 3 doses against severe disease (dengue haemorrhagic fever) which leads to hospitalisation for over half a million people (mostly children) every year, and 67 percent against dengue-associated hospitalisation.\n Dr Maria Rosario Capeding, lead author from the Research Institute for Tropical Medicine in the Philippines, said that their results suggest that vaccination with CYD-TDV could reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalisations.  This candidate vaccine had the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\n Professor Annelies Wilder-Smith from Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore said that perhaps the most interesting finding of this trial was that efficacy after at least one dose was almost as high as that after three dose because three doses 6 months apart was an inconvenient and costly immunisation schedule for scale up in national programmes, the question of whether sufficient efficacy could be achieved with a lower number of doses deserves further assessment.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14810938",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6814,
                    "source": {
                        "title": "Zee News",
                        "uri": "zeenews.india.com"
                    },
                    "time": "06:52:00",
                    "title": "First Dengue vaccine shows moderate improvement in phase 3 trial",
                    "uri": "196264249",
                    "url": "http://zeenews.india.com/news/health/health-news/first-dengue-vaccine-shows-moderate-improvement-in-phase-3-trial_28723.html",
                    "wgt": 1
                },
                {
                    "body": "Capping a 20-year effort to develop the world's first dengue fever vaccine, Sanofi ($SNY) has come through with positive results from a sweeping Phase III trial, but its candidate is not quite a panacea for the often deadly disease.\n Detailed results published in The Lancet showed Sanofi's shot reduced incidents of dengue by 56.5% in children aged 2 to 14, with an 88.5% reduction in hemorrhagic fever, a severe form of the disease.  The vaccine also cut the risk of hospitalization by 67%, a statistically significant mark.  The two-year study involved 10,275 children across Asia and dosed each with a three-shot regimen.\n Despite the vaccine's broad efficacy, however, a closer look at the data paints a more nuanced picture.  Dengue comes in four serotypes, and while Sanofi's treatment did well against variants 1, 3 and 4, it charted just 34.7% efficacy in serotype 2, missing statistical significance in one of Asia's most common forms of the disease.  Furthermore, the researchers note, the vaccine's efficacy increased with patient age, with the youngest patients deriving the least benefit.\n But, considering half the world's population is at risk of contracting dengue, \"this vaccine candidate, despite moderate overall efficacy, could have a substantial effect on public health,\" the investigators wrote, and Sanofi's treatment proved itself safe in the study.\n Now, Sanofi is waiting on the results of another 20,000-patient Phase III study, expected later this year, before filing for regulatory nods around the globe.  If approved, Sanofi's treatment would be the only vaccine on the market for a tropical disease that infects up to 100 million people a year, according to the World Health Organization.\n The company has spent more than $1.5 billion developing its dengue candidate, and now, with positive late-stage results in hand, Sanofi has glimpsed the finish line, hoping to launch the vaccine next year.\n \"After more than 20 years of commitment in collaboration with the scientific community, we are on course to make dengue the next vaccine-preventable disease,\" Sanofi Senior Vice President John Shiver said in a statement.  \"The public health implications of a future dengue vaccine are significant, and these findings are an important stride towards meeting the WHO's strategic goals of reducing dengue mortality by half and morbidity by at least 25% by 2020.\" \"\nAnalysts expect the shot to bring in about $1.4 billion a year at its peak, and Sanofi has already shelled out nearly $1 billion to set up a plant dedicated to producing the vaccine, allowing it to hit the ground running if and when the product is approved.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14852595",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6699,
                    "source": {
                        "title": "FierceBiotech",
                        "uri": "www.fiercebiotech.com"
                    },
                    "time": "15:03:00",
                    "title": "Sanofi's $1.5B dengue vaccine shows Phase III promise, but questions linger",
                    "uri": "196341267",
                    "url": "http://www.fiercebiotech.com/story/sanofis-15b-dengue-vaccine-shows-phase-iii-promise-questions-linger/2014-07-11?utm_medium=rss&utm_source=rss&utm_campaign=rss",
                    "wgt": 1
                },
                {
                    "body": "LONDON - Scientists have said that they have developed the world's first vaccine against dengue fever seen to work in large-scale trials.\n Research in the Lancet journal suggests more than 50 per cent of children who are given the vaccine are protected against the disease.\n Half the world's population is at risk of catching the mosquito-borne virus, BBC reported.  Experts said though the long-awaited study is promising, vaccines with greater effectiveness are crucial.  There are currently no treatments to prevent dengue fever - an illness which affects more than one million people a year.\n In the largest late-stage trial of a vaccine to date, researchers from five centres across Asia treated 6,000 children aged between two and 14 years old.\n Some 56 per cent were seen to have protection against the virus at the end of two years.  It worked best for children with certain subtypes of the virus and those who had been exposed to it before.\n The vaccine had an even greater impact on severe forms of the disease, reducing the number of people needing treatment in hospital and preventing 80 per cent of cases of haemorrhagic fever - a potentially life-threatening complication.\n Lead author Dr. Maria Rosario Capeding, from the Research Institute for Tropical Medicine in the Philippines, told the BBC \"Given that dengue is a major public health problem in most Asian countries the findings have the potential to have a huge impact on public health.\" \"\nThe doctor suggests people who have been given the vaccine should be monitored for at least five years to ensure it remains effective and safe.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14861544",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.656,
                    "source": {
                        "title": "DailyTimes",
                        "uri": "www.dailytimes.com.pk"
                    },
                    "time": "10:43:00",
                    "title": "First dengue vaccine developed",
                    "uri": "196354412",
                    "url": "http://www.dailytimes.com.pk/foreign/11-Jul-2014/first-dengue-vaccine-developed",
                    "wgt": 1
                },
                {
                    "body": "A new batch of results from a large-scale Phase III trial of Sanofi's ($SNY) dengue candidate holds mostly good news for the French drugmaker, which is on track to produce the world's first vaccine for the deadly disease.  But while the candidate showed itself to be by and large safe and effective, it once again faltered against serotype 2, the same variant that tripped it up in an earlier trial.\n In a study of 10,275 children aged 2 to 14 across Asia, Sanofi's jab reduced the incidence of dengue by 56.6%, results published in The Lancet show.  A three-shot regimen also cut hemorrhagic fever, a severe form of the disease, by 88.5% and reduced hospitalizations by 67%, hitting statistical significance.\n But while the vaccine successfully fought off dengue serotypes 1, 3 and 4, it posted just 34.7% efficacy in serotype 2, falling short of the statistical significance mark in one of the continent's more common forms of the disease.  It's not the first time serotype 2 has given the company fits, either.  Back in 2012, results from a Phase IIb trial revealed the vaccine had put up about 30% overall efficacy against it--way short of the estimate above 70% that Sanofi had banked on.\n Still, considering the vaccine's high safety marks and ability to cut down the overall risk of contracting dengue--which affects up to 100 million people per year--the results show its potential to have \"a significant impact on public health,\" lead researcher Dr. Maria Rosario Capeding said in a statement.\n Next up will be results from another Phase III study, which Sanofi will wait for before heading down the regulatory pathway.  And if it makes it to the end, there could be $1.4 billion in peak sales in the vaccine's future--a payoff that's been a long time coming for the pharma giant.\n \"These pivotal phase III vaccine efficacy study results take us closer to our ambition to bring the first vaccine against dengue to the world,\" John Shiver, R&D SVP at Sanofi Pasteur, said in a statement.  \"After more than 20 years of commitment in collaboration with the scientific community, we are on course to make dengue the next vaccine-preventable disease.\" \"",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14922921",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6531,
                    "source": {
                        "title": "FierceVaccines",
                        "uri": "www.fiercevaccines.com"
                    },
                    "time": "16:11:00",
                    "title": "Solid PhIII brings Sanofi closer to blockbuster dengue sales",
                    "uri": "196443411",
                    "url": "http://www.fiercevaccines.com/story/solid-phiii-brings-sanofi-closer-blockbuster-dengue-sales/2014-07-11",
                    "wgt": 1
                },
                {
                    "body": "Washington, July 11 (\nANI): The first dengue vaccine candidate (CYD-TDV) has shown moderate protection (56 percent) against the disease in Asian children in phase 3 clinical testing, according to a new research.\n The vaccine also showed 88.5 percent efficacy after 3 doses against severe disease (dengue haemorrhagic fever) which leads to hospitalisation for over half a million people (mostly children) every year, and 67 percent against dengue-associated hospitalisation.\n Dr Maria Rosario Capeding, lead author from the Research Institute for Tropical Medicine in the Philippines, said that their results suggest that vaccination with CYD-TDV could reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalisations.  This candidate vaccine had the potential to have a significant impact on public health in view of the high disease burden in endemic countries.\n Professor Annelies Wilder-Smith from Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore said that perhaps the most interesting finding of this trial was that efficacy after at least one dose was almost as high as that after three dose because three doses 6 months apart was an inconvenient and costly immunisation schedule for scale up in national programmes, the question of whether sufficient efficacy could be achieved with a lower number of doses deserves further assessment.\n Smith added that for the moment, the CYD-TDV vaccine was the best they had, however, with 56percent efficacy it would never be a single solution.\n The study is published in The Lancet.  (\nANI)",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14788829",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6417,
                    "source": {
                        "title": "http://aninews.in",
                        "uri": "www.aninews.in"
                    },
                    "time": "05:03:00",
                    "title": "First Dengue vaccine shows moderate improvement in phase 3 trial",
                    "uri": "196221925",
                    "url": "http://www.aninews.in/newsdetail10/story175291/first-dengue-vaccine-shows-moderate-improvement-in-phase-3-trial.html",
                    "wgt": 1
                },
                {
                    "body": "News outlets report on a study that finds an experimental dengue vaccine shows promising results in clinical trials.\n Bloomberg Businessweek: Dengue Vaccine Shows Promise Against 3 Out of 4 Viruses\n\"The most advanced experimental vaccine against dengue protected some children against the disease in a study, though a more effective weapon may still be needed to curb the most widespread mosquito-borne infection...\" (Bennett, 7/11).\n HealthDay News: Dengue Fever Vaccine Shows Some Promise in Trial\n\"...W While the vaccine only prevented dengue fever in 56 percent of the 10,000 kids who got the full series of three shots, it protected more than 88 percent of them from severe disease.  In the worst-case scenarios, dengue fever can lead to hospitalization, and sometimes death...\" (Reinberg, 7/10).\n Reuters: Sanofi dengue vaccine promising but questions remain\n\"...T The late-stage trial involved 10,275 healthy children aged 2-14 across five countries in Asia, a region that accounts for over two-thirds of the mosquito-borne disease's global burden.  Sanofi had already disclosed in April that its vaccine reduced the incidence of dengue fever by 56 percent in the Asian study, without giving details.  The full findings were published online on Friday in The Lancet medical journal...\" (Huet, 7/10).\n VOA News: Vaccine And Other Strategies May Soon Control Dengue Fever\n\"...A Another large scale study is taking place in Latin America.  Sanofi Pasteur, the manufacturer, says the vaccine could be available by 2015...\" (Pearson, 7/10).",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14857198",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.6336,
                    "source": {
                        "title": "kff.org",
                        "uri": "kff.org"
                    },
                    "time": "15:25:00",
                    "title": "Experimental Dengue Vaccine Shows Positive Results In Study Among Asian Children",
                    "uri": "196346382",
                    "url": "http://kff.org/news-summary/experimental-dengue-vaccine-shows-positive-results-in-study-among-asian-children/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A%2Bkff%252Fkdghprch%2B%2528Kaiser%2BDaily%2BGlobal%2BHealth%2BPolicy%2BReport%2B-%2BMaternal%252C%2BNewborn%2BHealth%2Band%2BChild%2BHealth%2529",
                    "wgt": 1
                },
                {
                    "body": "The world's most advanced vaccine against dengue fever may offer only moderate protection but it could still help millions of people avoid the devastating effects of the disease, latest trial shows.\n 10,275 healthy children aged 2-14 across five countries in Asia, namely Indonesia, Malaysia, Thailand, the Philippines and Vietnam, were involved in the trial developed by French pharmaceutical company Sanofi.\n Asia is the region with two-thirds of all the mosquito-borne cases worldwide.  The disease sickens about 100 million people every year, mostly in Asia, Africa and Latin America, but there is no treatment for dengue whose most common symptoms include fever, severe joint pain, headaches and bleeding.\n Researchers followed the children both in the vaccine group and the control group (those who got the fake shot) for about two years.  Findings of a study published online on Friday in The Lancet medical journal show that the vaccine was safe and reduced the most serious cases of haemorrhagic fever by nearly 90 per cent. However, it didn't provide sufficient protection to young children who are at the greatest risk, nor did it efficiently fight one of the disease's four strains.\n The shot's efficacy improved in the latest study to 56 per cent compared to 33 per cent in 2012 early trial.\n \"In view of the high disease burden in endemic countries... this vaccine candidate, despite moderate overall efficacy, could have a substantial effect on public health,\" the scientists behind the study wrote.\n Some analysts estimate that the three-dose vaccine could sell 1 billion euros a year, significantly boosting Sanofi's vaccines business.  However, some doubts have emerged as to whether three shots of the vaccine are really needed, since one of the findings from the latest study showed almost the same efficacy after at least one dose as after three doses.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14832268",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.606,
                    "source": {
                        "title": "News on Wellness",
                        "uri": "www.newsonwellness.com"
                    },
                    "time": "09:11:00",
                    "title": "Sanofi's Dengue Vaccine Shows Improvement On Efficacy",
                    "uri": "196301988",
                    "url": "http://www.newsonwellness.com/2014/07/sanofis-dengue-vaccine-shows-improvement-efficacy/",
                    "wgt": 1
                },
                {
                    "body": "Paris (AFP) - A prototype vaccine for dengue that two years ago yielded lukewarm results has proved more effective after wider trials and is a potential arm against the disease, researchers said Friday.\n Devised by the French pharmaceutical giant Sanofi Pasteur, the so-called CYD-TDV vaccine provided only 30 percent protection against the dangerous fever when first tested among children in Thailand.\n Widened to trials in four other Asian countries, where disease conditions vary greatly, the vaccine's protection has been shown to be significantly higher, at 56.5 percent overall, the scientists said.\n The result falls short of the benchmark set by classic vaccines such as those for polio and measles, which can be more than 99 percent effective.  One reason for this is that CYD-TDV performed poorly against one of the four strains of dengue virus, the investigators reported in The Lancet.\n These strains, or serotypes, circulate simultaneously, which means a vaccine should ideally protect against all of them.  Even so, the prototype was safe and well tolerated and its shield, if only partial, means it should be enlisted in the fi ght against dengue, they argued.\n \"Our results suggest that vaccination with CYD-TDV can reduce the incidence of symptomatic dengue infection by more than half and importantly reduced severe disease and hospitalizations,\" said Maria Rosario Capeding from the Philippines' Research Institute for Tropical Medicine.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14950687",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.5936,
                    "source": {
                        "title": "Tempo - News in a Flash",
                        "uri": "www.tempo.com.ph"
                    },
                    "time": "23:30:00",
                    "title": "Test vaccine for dengue promising",
                    "uri": "196452140",
                    "url": "http://www.tempo.com.ph/2014/07/test-vaccine-for-dengue-promising/?utm_medium=twitter&utm_source=twitterfeed",
                    "wgt": 1
                },
                {
                    "body": "Bill & Melinda Gates Foundation's \"Impatient Optimists\": A Potential Breakthrough in the Fight against Dengue Fever\nLance Gordon, director for neglected infectious diseases in the Gates Foundation's Global Health Program, discusses the news that a Sanofi Pasteur experimental dengue vaccine showed positive clinical trial results and the foundation's commitment to assisting global partners in finding an effective vaccine against the disease (7/10).",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14840231",
                    "isDuplicate": false,
                    "lang": "eng",
                    "sim": 0.3453,
                    "source": {
                        "title": "kff.org",
                        "uri": "kff.org"
                    },
                    "time": "13:50:00",
                    "title": "Gates Foundation Committed To Finding Safe, Accessible Dengue Vaccine",
                    "uri": "196316473",
                    "url": "http://kff.org/news-summary/gates-foundation-committed-to-finding-safe-accessible-dengue-vaccine/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A%2Bkff%252Fkdghpr%2B%2528Kaiser%2BDaily%2BGlobal%2BHealth%2BPolicy%2BReport%2529",
                    "wgt": 1
                }
            ]
        },
        "info": {
            "articleCount": 20,
            "averageDate": "2014-07-11",
            "avgCos": 0.6196,
            "categories": [
                {
                    "label": "Health/Child_Health/Immunizations",
                    "uri": "http://www.dmoz.org/Health/Child_Health/Immunizations",
                    "wgt": 37
                }
            ],
            "customDate": false,
            "customLocation": false,
            "eventUri": "970955",
            "extractedDate": "",
            "extractedDateEnd": "",
            "id": "963928",
            "lang": "eng",
            "storyDate": "2014-07-11",
            "storyDateEnd": "",
            "uri": "850f305d-14db-4c75-b547-79470a557ea3-553531",
            "variance": 0.4661
        }
    },
    "e7e700df-6a06-44ea-a4f3-f736278fc36b-143568": {
        "articles": {
            "resultCount": 10,
            "results": [
                {
                    "body": "PAR\u00cdS.  La primera vacuna contra la fiebre del dengue, de la francesa Sanofi, brind\u00f3 una protecci\u00f3n moderada en un gran estudio cl\u00ednico.\n Sin embargo, persisten las preguntas sobre cu\u00e1nto puede ayudar a combatir la enfermedad tropical de crecimiento m\u00e1s r\u00e1pido en el mundo.  La prueba en etapas avanzadas involucr\u00f3 a 10.275 ni\u00f1os sanos de entre 2 y 14 a\u00f1os en cinco pa\u00edses de Asia, una regi\u00f3n que corresponde a m\u00e1s de dos tercios de los casos globales de la enfermedad transmitida por mosquitos.\n Sanofi ya hab\u00eda revelado en abril que su vacuna redujo la incidencia de dengue en un 56 por ciento en el estudio en Asia, sin entregar detalles.  Los hallazgos completos fueron publicados en l\u00ednea el viernes en la revista m\u00e9dica The Lancet.  El estudio hall\u00f3 que la vacuna era segura y redujo los casos m\u00e1s graves de fiebre hemorr\u00e1gica en casi un 90 por ciento.  Pero ofreci\u00f3 poca protecci\u00f3n a los ni\u00f1os peque\u00f1os -los que corren mayor riesgo de contraer el dengue- y result\u00f3 especialmente ineficiente frente a una de las cuatro cepas de la enfermedad viral.\n Los resultados sugieren que la nueva vacuna act\u00faa mejor como un estimulador inmunol\u00f3gico para pacientes con exposici\u00f3n previa, y por lo tanto, podr\u00eda ser m\u00e1s \u00fatil en las regiones tropicales donde el dengue es com\u00fan, m\u00e1s que como vacuna para los turistas.  Como no existe una vacuna por el momento, el nuevo medicamento podr\u00eda ser un arma importante en la lucha contra el dengue.\n \"Considerando la elevada carga sanitaria en pa\u00edses en que el dengue es end\u00e9mico (...) esta posible vacuna, a pesar de tener una eficiencia general moderada, podr\u00eda tener un efecto sustancial en la salud p\u00fablica\", escribieron los cient\u00edficos responsables del estudio.\n El estudio fue liderado por Maria Rosario Capeding del Instituto de Investigaci\u00f3n para Medicina Tropical en Las Filipinas, y fue financiado por Sanofi.  Casi la mitad de la poblaci\u00f3n del mundo corre riesgo de contraer la fiebre del dengue -tambi\u00e9n conocida como \"fiebre rompehuesos\" debido al agudo dolor que puede provocar.  La enfermedad infecta a unos 100 millones de personas cada a\u00f1o, seg\u00fan la Organizaci\u00f3n Mundial de la Salud, y algunos expertos estiman que la cifra es tres veces m\u00e1s grande.\n La mayor\u00eda de los pacientes sobreviven al dengue, pero la enfermedad mata a un total estimado de 20.000 personas cada a\u00f1o, muchos de ellos ni\u00f1os, y motiva una hospitalizaci\u00f3n cada minuto en todo el mundo.  Sanofi ha invertido m\u00e1s de 1.300 millones de euros (1.770 millones de d\u00f3lares) en los \u00faltimos 20 a\u00f1os en el desarrollo de la vacuna, que est\u00e1 varios a\u00f1os adelantada a sus posibles competidores, y ha construido una f\u00e1brica especializada en Lyon, en el sur de Francia, con capacidad para producir 100 millones de dosis al a\u00f1o.\n Sanofi a\u00fan prueba su vacuna en 20.000 ni\u00f1os en Am\u00e9rica Latina y Guillaume Leroy, jefe de su programa de vacuna del dengue, dijo que esperar\u00eda por los resultados de ese \u00faltimo estudio -que se conocer\u00e1n a final de a\u00f1o- antes de buscar la aprobaci\u00f3n de los reguladores en pa\u00edses end\u00e9micos el pr\u00f3ximo a\u00f1o.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14858723",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.8966,
                    "source": {
                        "title": "ABC Color",
                        "uri": "www.abc.com.py"
                    },
                    "time": "15:41:00",
                    "title": "Vacuna contra el dengue es prometedora, pero persisten dudas",
                    "uri": "196351426",
                    "url": "http://www.abc.com.py/ciencia/vacuna-contra-el-dengue-de-sanofi-es-prometedora-pero-persisten-dudas-1265120.html",
                    "wgt": 1
                },
                {
                    "body": "PAR\u00cdS (Reuters) - La primera vacuna contra la fiebre del dengue, de la francesa SANOFI (SAN.P PA) brind\u00f3 una protecci\u00f3n moderada en un gran estudio cl\u00ednico, pero persisten las preguntas sobre cu\u00e1nto puede ayudar a combatir la enfermedad tropical de crecimiento m\u00e1s r\u00e1pido en el mundo.\n La prueba en etapas avanzadas involucr\u00f3 a 10.275 ni\u00f1os sanos de entre 2 y 14 a\u00f1os en cinco pa\u00edses de Asia, una regi\u00f3n que corresponde a m\u00e1s de dos tercios de los casos globales de la enfermedad transmitida por mosquitos.\n Sanofi ya hab\u00eda revelado en abril que su vacuna redujo la incidencia de dengue en un 56 por ciento en el estudio en Asia, sin entregar detalles.  Los hallazgos completos fueron publicados en l\u00ednea el viernes en la revista m\u00e9dica The Lancet.\n El estudio hall\u00f3 que la vacuna era segura y redujo los casos m\u00e1s graves de fiebre hemorr\u00e1gica en casi un 90 por ciento.  Pero ofreci\u00f3 poca protecci\u00f3n a los ni\u00f1os peque\u00f1os -los que corren mayor riesgo de contraer el dengue- y result\u00f3 especialmente ineficiente frente a una de las cuatro cepas de la enfermedad viral.\n Los resultados sugieren que la nueva vacuna act\u00faa mejor como estimulador inmunol\u00f3gico para pacientes con exposici\u00f3n previa, y por lo tanto, podr\u00eda ser m\u00e1s \u00fatil en las regiones tropicales donde el dengue es com\u00fan, m\u00e1s que como vacuna para los turistas.\n Como no existe una vacuna por el momento, el nuevo medicamento podr\u00eda ser un arma importante en la lucha contra el dengue.\n \"Considerando la elevada carga sanitaria en pa\u00edses en que el dengue es end\u00e9mico (...) esta posible vacuna, a pesar de tener una eficiencia general moderada, podr\u00eda tener un efecto sustancial en la salud p\u00fablica\", escribieron los cient\u00edficos responsables del estudio.\n El estudio fue liderado por Maria Rosario Capeding del Instituto de Investigaci\u00f3n para Medicina Tropical en Las Filipinas, y fue financiado por Sanofi.\n Casi la mitad de la poblaci\u00f3n del mundo corre riesgo de contraer la fiebre del dengue -tambi\u00e9n conocida como \"fiebre rompehuesos\" debido al agudo dolor que puede provocar.  La enfermedad infecta a unos 100 millones de personas cada a\u00f1o, seg\u00fan la Organizaci\u00f3n Mundial de la Salud, y algunos expertos estiman que la cifra es tres veces m\u00e1s grande.\n La mayor\u00eda de los pacientes sobreviven al dengue, pero la enfermedad mata a un total estimado de 20.000 personas cada a\u00f1o, muchos de ellos ni\u00f1os, y motiva una hospitalizaci\u00f3n cada minuto en todo el mundo.\n Sanofi ha invertido m\u00e1s de 1.300 millones de euros (1.770 millones de d\u00f3lares) en los \u00faltimos 20 a\u00f1os en el desarrollo de la vacuna, que est\u00e1 varios a\u00f1os adelantada a sus posibles competidores, y ha construido una f\u00e1brica especializada en Lyon, en el sur de Francia, con capacidad para producir 100 millones de dosis al a\u00f1o.\n Sanofi a\u00fan prueba su vacuna en 20.000 ni\u00f1os en Am\u00e9rica Latina y Guillaume Leroy, jefe de su programa de vacuna del dengue, dijo que esperar\u00eda por los resultados de ese \u00faltimo estudio -que se conocer\u00e1n a final de a\u00f1o- antes de buscar la aprobaci\u00f3n de los reguladores en pa\u00edses end\u00e9micos el pr\u00f3ximo a\u00f1o.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14853494",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.896,
                    "source": {
                        "title": "El Economista",
                        "uri": "www.eleconomista.es"
                    },
                    "time": "15:09:00",
                    "title": "La vacuna contra el dengue de Sanofi promete, pero persisten dudas",
                    "uri": "196204858",
                    "url": "http://www.eleconomista.es/cultura/noticias/5932864/07/14/La-vacuna-contra-el-dengue-de-Sanofi-promete-pero-persisten-dudas.html",
                    "wgt": 1
                },
                {
                    "body": "La primera vacuna contra la fiebre del dengue, de la francesa Sanofi, brind\u00f3 una ...\n Por Natalie Huet\nPAR\u00cdS (Reuters) - La primera vacuna contra la fiebre del dengue, de la francesa Sanofi, brind\u00f3 una protecci\u00f3n moderada en un gran estudio cl\u00ednico, pero persisten las preguntas sobre cu\u00e1nto puede ayudar a combatir la enfermedad tropical de crecimiento m\u00e1s r\u00e1pido en el mundo.\n La prueba en etapas avanzadas involucr\u00f3 a 10.275 ni\u00f1os sanos de entre 2 y 14 a\u00f1os en cinco pa\u00edses de Asia, una regi\u00f3n que corresponde a m\u00e1s de dos tercios de los casos globales de la enfermedad transmitida por mosquitos.\n Sanofi ya hab\u00eda revelado en abril que su vacuna redujo la incidencia de dengue en un 56 por ciento en el estudio en Asia, sin entregar detalles.  Los hallazgos completos fueron publicados en l\u00ednea el viernes en la revista m\u00e9dica The Lancet.\n El estudio hall\u00f3 que la vacuna era segura y redujo los casos m\u00e1s graves de fiebre hemorr\u00e1gica en casi un 90 por ciento.  Pero ofreci\u00f3 poca protecci\u00f3n a los ni\u00f1os peque\u00f1os -los que corren mayor riesgo de contraer el dengue- y result\u00f3 especialmente ineficiente frente a una de las cuatro cepas de la enfermedad viral.\n Los resultados sugieren que la nueva vacuna act\u00faa mejor como estimulador inmunol\u00f3gico para pacientes con exposici\u00f3n previa, y por lo tanto, podr\u00eda ser m\u00e1s \u00fatil en las regiones tropicales donde el dengue es com\u00fan, m\u00e1s que como vacuna para los turistas.\n Como no existe una vacuna por el momento, el nuevo medicamento podr\u00eda ser un arma importante en la lucha contra el dengue.\n \"Considerando la elevada carga sanitaria en pa\u00edses en que el dengue es end\u00e9mico (...) esta posible vacuna, a pesar de tener una eficiencia general moderada, podr\u00eda tener un efecto sustancial en la salud p\u00fablica\", escribieron los cient\u00edficos responsables del estudio.\n El estudio fue liderado por Maria Rosario Capeding del Instituto de Investigaci\u00f3n para Medicina Tropical en Las Filipinas, y fue financiado por Sanofi.\n Casi la mitad de la poblaci\u00f3n del mundo corre riesgo de contraer la fiebre del dengue -tambi\u00e9n conocida como \"fiebre rompehuesos\" debido al agudo dolor que puede provocar.  La enfermedad infecta a unos 100 millones de personas cada a\u00f1o, seg\u00fan la Organizaci\u00f3n Mundial de la Salud, y algunos expertos estiman que la cifra es tres veces m\u00e1s grande.\n La mayor\u00eda de los pacientes sobreviven al dengue, pero la enfermedad mata a un total estimado de 20.000 personas cada a\u00f1o, muchos de ellos ni\u00f1os, y motiva una hospitalizaci\u00f3n cada minuto en todo el mundo.\n Sanofi ha invertido m\u00e1s de 1.300 millones de euros (1.770 millones de d\u00f3lares) en los \u00faltimos 20 a\u00f1os en el desarrollo de la vacuna, que est\u00e1 varios a\u00f1os adelantada a sus posibles competidores, y ha construido una f\u00e1brica especializada en Lyon, en el sur de Francia, con capacidad para producir 100 millones de dosis al a\u00f1o.\n Sanofi a\u00fan prueba su vacuna en 20.000 ni\u00f1os en Am\u00e9rica Latina y Guillaume Leroy, jefe de su programa de vacuna del dengue, dijo que esperar\u00eda por los resultados de ese \u00faltimo estudio -que se conocer\u00e1n a final de a\u00f1o- antes de buscar la aprobaci\u00f3n de los reguladores en pa\u00edses end\u00e9micos el pr\u00f3ximo a\u00f1o.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14788429",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.8959,
                    "source": {
                        "title": "es.noticias.yahoo.com",
                        "uri": "es.noticias.yahoo.com"
                    },
                    "time": "07:57:00",
                    "title": "Vaccine against dengue of Sanofi promises, but doubts remain",
                    "uri": "196212123",
                    "url": "https://es.noticias.yahoo.com/vacuna-dengue-sanofi-promete-persisten-dudas-060557403--finance.html",
                    "wgt": 1
                },
                {
                    "body": "PAR\u00cdS (Reuters) - La primera vacuna contra la fiebre del dengue, de la francesa Sanofi, brind\u00f3 una protecci\u00f3n moderada en un gran estudio cl\u00ednico, pero persisten las preguntas sobre cu\u00e1nto puede ayudar a combatir la enfermedad tropical de crecimiento m\u00e1s r\u00e1pido en el mundo.\n La prueba en etapas avanzadas involucr\u00f3 a 10.275 ni\u00f1os sanos de entre 2 y 14 a\u00f1os en cinco pa\u00edses de Asia, una regi\u00f3n que corresponde a m\u00e1s de dos tercios de los casos globales de la enfermedad transmitida por mosquitos.\n Sanofi ya hab\u00eda revelado en abril que su vacuna redujo la incidencia de dengue en un 56 por ciento en el estudio en Asia, sin entregar detalles.  Los hallazgos completos fueron publicados en l\u00ednea el viernes en la revista m\u00e9dica The Lancet.\n El estudio hall\u00f3 que la vacuna era segura y redujo los casos m\u00e1s graves de fiebre hemorr\u00e1gica en casi un 90 por ciento.  Pero ofreci\u00f3 poca protecci\u00f3n a los ni\u00f1os peque\u00f1os -los que corren mayor riesgo de contraer el dengue- y result\u00f3 especialmente ineficiente frente a una de las cuatro cepas de la enfermedad viral.\n Los resultados sugieren que la nueva vacuna act\u00faa mejor como un estimulador inmunol\u00f3gico para pacientes con exposici\u00f3n previa, y por lo tanto, podr\u00eda ser m\u00e1s \u00fatil en las regiones tropicales donde el dengue es com\u00fan, m\u00e1s que como vacuna para los turistas.\n Como no existe una vacuna por el momento, el nuevo medicamento podr\u00eda ser un arma importante en la lucha contra el dengue.\n \"Considerando la elevada carga sanitaria en pa\u00edses en que el dengue es end\u00e9mico (...) esta posible vacuna, a pesar de tener una eficiencia general moderada, podr\u00eda tener un efecto sustancial en la salud p\u00fablica\", escribieron los cient\u00edficos responsables del estudio.\n El estudio fue liderado por Maria Rosario Capeding del Instituto de Investigaci\u00f3n para Medicina Tropical en Las Filipinas, y fue financiado por Sanofi.  Continuaci\u00f3n...",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14772880",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.8546,
                    "source": {
                        "title": "lta.reuters.com",
                        "uri": "lta.reuters.com"
                    },
                    "time": "06:32:00",
                    "title": "Vaccine against dengue of Sanofi is promising, but doubts remain",
                    "uri": "196202025",
                    "url": "http://lta.reuters.com/article/worldNews/idLTAKBN0FG05E20140711",
                    "wgt": 1
                },
                {
                    "body": "LONDRES / AP - La vacuna m\u00e1s avanzada contra el dengue s\u00f3lo ofrece una protecci\u00f3n moderada, no obstante podr\u00eda ayudar a millones de personas a evitar los efectos devastadores de la enfermedad, seg\u00fan un estudio amplio.\n No existe tratamiento para el dengue, el cual ocasiona fiebre, dolor severo de articulaciones, dolor de cabeza y hemorragia.  Aproximadamente la mitad de la poblaci\u00f3n mundial est\u00e1 en riesgo de contraer la enfermedad transmitida por un mosquito, que infecta a cerca de 100 millones de personas cada a\u0144o, mayormente en Asia, \u00c1frica y Latinoam\u00e9rica.\n Los resultados de una prueba inicial a la vacuna en 2012 encontraron que su eficacia era de 33% y que no proteg\u00eda contra uno de los tipos de dengue.  Existen cuatro tipos distintos, y la vacuna fue creada para combatirlos todos.  En la prueba m\u00e1s reciente, realizada en m\u00e1s de 10.000 ni\u0144os de entre 2 y 14 a\u0144os en Indonesia, Malasia, Tailandia, Filipinas y Vietnam, la eficacia de la vacuna mejor\u00f3 a 56%.  Las vacunas m\u00e1s comunes, como la de sarampi\u00f3n y poliomielitis, tienen una eficacia de m\u00e1s de 95%.\n \"Todos nosotros hubi\u00e9ramos deseado una mejor tasa de eficacia, pero esto es con lo que tenemos que vivir por el momento\", dijo Annelies Wilder-Smith, de la Universidad Tecnol\u00f3gica de Nanyang en Singapur, quien escribi\u00f3 un comentario para el estudio, el cual fue publicado el viernes en la revista Lancet.  \"Si la eficacia de esta vacuna es suficiente para que inviertan los pa\u00edses, es una pregunta que deben responder los economistas\".\n Investigadores siguieron la pista a los ni\u0144os del estudio nuevo durante aproximadamente dos a\u0144os y notaron efectos secundarios como infecciones y lesiones.  El estudio fue pagado por Sanofi Pasteur, fabricante de la vacuna.\n Otros expertos dijeron que se requieren cifras de un seguimiento m\u00e1s prolongado a ni\u0144os vacunados para valorar la seguridad de la vacuna.  La gente infectada con un tipo de dengue desarrolla anticuerpos que protegen contra nuevas infecciones de ese tipo; pero si se infectan con otro tipo de dengue, sus anticuerpos los hacen susceptibles a una enfermedad m\u00e1s grave que podr\u00eda incluir hemorragia.  A algunos cient\u00edficos les preocupa que los anticuerpos de una vacuna contra el dengue pudieran tener el mismo efecto, y dijeron que los ni\u0144os vacunados deber\u00edan ser monitoreados durante varios a\u0144os.\n Redacci\u00f3n",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14781130",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.808,
                    "source": {
                        "title": "Aguasdigital",
                        "uri": "www.aguasdigital.com"
                    },
                    "time": "07:21:00",
                    "title": "Dengue vaccine offers some protection",
                    "uri": "196212154",
                    "url": "http://www.aguasdigital.com/actualidad/leer.php?idnota=49522",
                    "wgt": 1
                },
                {
                    "body": "LONDRES, AP. La vacuna m\u00e1s avanza contra el dengue s\u00f3lo ofrece una protecci\u00f3n moderada, no obstante podr\u00eda ayudar a millones de personas a evitar los efectos devastadores de la enfermedad, seg\u00fan un estudio amplio.\n No existe tratamiento para el dengue, el cual ocasiona fiebre, dolor severo de articulaciones, dolor de cabeza y hemorragia.  Aproximadamente la mitad de la poblaci\u00f3n mundial est\u00e1 en riesgo de contraer la enfermedad transmitida por un mosquito, que infecta a cerca de 100 millones de personas cada a\u00f1o, mayormente en Asia, \u00c1frica y Latinoam\u00e9rica.\n Los resultados de una prueba inicial a la vacuna en 2012 encontraron que su eficacia era de 33% y que no proteg\u00eda contra uno de los tipos de dengue.  Existen cuatro tipos distintos, y la vacuna fue creada para combatirlos todos.\n En la prueba m\u00e1s reciente, realizada en m\u00e1s de 10.000 ni\u00f1os de entre 2 y 14 a\u00f1os en Indonesia, Malasia, Tailandia, Filipinas y Vietnam, la eficacia de la vacuna mejor\u00f3 a 56%.  Las vacunas m\u00e1s comunes, como la de sarampi\u00f3n y poliomielitis, tienen una eficacia de m\u00e1s de 95%.\n \"Todos nosotros hubi\u00e9ramos deseado una mejor tasa de eficacia, pero esto es con lo que tenemos que vivir por el momento\", dijo Annelies Wilder-Smith, de la Universidad Tecnol\u00f3gica de Nanyang en Singapur, quien escribi\u00f3 un comentario para el estudio, el cual fue publicado el viernes en la revista Lancet.  \"Si la eficacia de esta vacuna es suficiente para que inviertan los pa\u00edses, es una pregunta que deben responder los economistas\".\n Investigadores siguieron la pista a los ni\u00f1os del estudio nuevo durante aproximadamente dos a\u00f1os y notaron efectos secundarios como infecciones y lesiones.  El estudio fue pagado por Sanofi Pasteur, fabricante de la vacuna.\n Otros expertos dijeron que se requieren cifras de un seguimiento m\u00e1s prolongado a ni\u00f1os vacunados para valorar la seguridad de la vacuna.  La gente infectada con un tipo de dengue desarrolla anticuerpos que protegen contra nuevas infecciones de ese tipo; pero si se infectan con otro tipo de dengue, sus anticuerpos los hacen susceptibles a una enfermedad m\u00e1s grave que podr\u00eda incluir hemorragia.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14780941",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.7972,
                    "source": {
                        "title": "hoy.com.do",
                        "uri": "hoy.com.do"
                    },
                    "time": "07:21:00",
                    "title": "Dengue vaccine offers some protection",
                    "uri": "196212152",
                    "url": "http://hoy.com.do/vacuna-contra-dengue-ofrece-algo-de-proteccion/",
                    "wgt": 1
                },
                {
                    "body": "Reduce en 88,5 % la posibilidad de tener dengue hemorr\u00e1gico y en 67 % las hospitalizaciones.  Est\u00e1 probada en ni\u00f1os hasta los 14 a\u00f1os y requiere tres dosis.  Sanofi Pasteur, divisi\u00f3n de vacunas de Sanofi, acaba de publicar un trabajo en \"The Lancet\" acerca de los resultados de las pruebas cl\u00ednicas de su vacuna contra el dengue.\n Se trata de la publicaci\u00f3n de los resultados detallados del primer estudio de eficacia de fase III de su vacuna contra el dengue realizado en cinco pa\u00edses de Asia.  Los resultados mostraron una eficacia global contra el dengue sintom\u00e1tico de 56,5%* en ni\u00f1os de entre 2 y 14 a\u00f1os de edad luego de la tercera dosis del esquema de vacunaci\u00f3n.  Es importante destacar que el an\u00e1lisis muestra 88,5% de reducci\u00f3n de la fiebre hemorr\u00e1gica por dengue, la forma severa del dengue, de acuerdo al criterio de la OMS.  Tambi\u00e9n mostr\u00f3 una importante reducci\u00f3n cl\u00ednica en el riesgo de hospitalizaciones por dengue de 67% durante el estudio.  El perfil de seguridad favorable de la vacuna, observado durante 25 meses de seguimiento del estudio de fase III en Asia, es consistente con el perfil de seguridad documentado en otros estudios.\n El dengue es una amenaza para casi la mitad de la poblaci\u00f3n mundial, y es una prioridad de salud p\u00fablica apremiante en muchos pa\u00edses de Asia y Latinoam\u00e9rica donde ocurren epidemias.  El estudio confirm\u00f3 la alta carga de la enfermedad revelando que uno de cada 20 ni\u00f1os en el grupo control sufri\u00f3 de dengue anualmente, cifra tres veces mayor a la esperada inicialmente.  Cada a\u00f1o, se estima que 500.000 personas, incluyendo ni\u00f1os y ni\u00f1as, padecen de dengue severo requiriendo hospitalizaci\u00f3n.2 Esto provoca una alta carga en hospitales y en los sistemas de salud durante los brotes.\n \"Los resultados de este primer estudio de fase III muestran el potencial de la vacuna de tener un impacto significativo en la salud p\u00fablica\" coment\u00f3 Mar\u00eda Rosario Capeding, investigadora principal del estudio, del Instituto de Investigaci\u00f3n de Medicina Tropical de Filipinas.  \"La amenaza de la enfermedad severa por dengue crea miedo en la comunidad.  El impacto de la vacuna en la prevenci\u00f3n de la fiebre hemorr\u00e1gica es notable.  Una vacuna que es capaz de evitar el sufrimiento de personas y reducir significativamente la carga en la salud, cambiar\u00e1 la vida de millones\"\nEl an\u00e1lisis de seguridad (reacciones solicitadas, eventos no solicitados y Eventos Adversos Graves) mostr\u00f3 porcentajes de reporte similares entre el grupo de vacunados y el grupo control.  Los Eventos Adversos Graves fueron consistentes con las condiciones m\u00e9dicas del grupo de edad y estuvieron principalmente relacionadas con infecciones y accidentes.  La seguridad de la vacuna es continuamente revisada por un comit\u00e9 de seguimiento independiente.  A la fecha 27.000 ni\u00f1os y ni\u00f1as, adolescentes y adultos han sido vacunados, a lo largo de los estudios cl\u00ednicos, con 3 dosis de la vacuna candidata contra el dengue de Sanofi Pasteur.\n \"La alta eficacia observada contra el dengue severo y la reducci\u00f3n de las hospitalizaciones en dos terceras partes es un resultado extremadamente importante para la salud p\u00fablica.  M\u00e1s a\u00fan, esta vacuna contin\u00faa alcanzando las altas expectativas de seguridad, lo que es muy positivo,\" coment\u00f3 Duane Gubler, profesor y director fundador del Programa de Investigaci\u00f3n de Autor sobre Enfermedades Infecciosas Emergentes, Duke-NUS Escuela M\u00e9dica de Graduados, Singapur, y presidente de la Alianza para el Control del Dengue (PDC por sus siglas en ingl\u00e9s).\n \"Estos estudios pivotes de eficacia de fase III de la vacuna prueban que estamos cerca de dar al mundo la primera vacuna contra el dengue\" dijo John Shiver, vicepresidente s\u00e9nior de Investigaci\u00f3n y Desarrollo de Sanofi Pasteur.  \"Luego de m\u00e1s de 20 a\u00f1os de compromiso en colaboraci\u00f3n con la comunidad cient\u00edfica, estamos a punto de hacer del dengue, la pr\u00f3xima enfermedad prevenible por vacunaci\u00f3n.  Las implicaciones de salud p\u00fablica de una futura vacuna contra el dengue son significativas y estos hallazgos son un importante hito en el camino hacia alcanzar las metas estrat\u00e9gicas de la OMS de reducir la mortalidad del dengue a la mitad y la mortalidad en alrededor de un 25% para 2020.\" \"\nLos cuatro serotipos del virus del dengue han circulado durante el estudio con una distribuci\u00f3n que es representativa de la epidemiolog\u00eda en Asia.  La eficacia de la vacuna durante los 25 meses de observaci\u00f3n del estudio es consistente a trav\u00e9s de los pa\u00edses y parece variar por serotipo de dengue (entre 34,7% y 72,4%) y por edad.  Los resultados de este primer estudio de eficacia de fase III a gran escala ser\u00e1n complementados por los resultados de un segundo estudio de fase III de gran escala conducido en Latinoam\u00e9rica y el Caribe, que incluy\u00f3 a m\u00e1s de 20.000 ni\u00f1os y ni\u00f1as y adolescentes de entre 9 y 16 a\u00f1os de edad de Brasil, Colombia, Honduras, M\u00e9xico y Puerto Rico.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14773031",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.7627,
                    "source": {
                        "title": "El Universal de Caracas",
                        "uri": "www.eluniversal.com"
                    },
                    "time": "06:32:00",
                    "title": "Announcing the creation of a vaccine effective against dengue",
                    "uri": "196202044",
                    "url": "http://www.eluniversal.com/vida/140710/anuncian-la-creacion-de-una-vacuna-eficaz-contra-el-dengue",
                    "wgt": 1
                },
                {
                    "body": "LONDRES, Inglaterra.( (AP) La vacuna m\u00c3\u00a1s avanza contra el dengue s\u00c3\u00b3lo ofrece una protecci\u00c3\u00b3n moderada, no obstante podr\u00c3\u00ada ayudar a millones de personas a evitar los efectos devastadores de la enfermedad, seg\u00c3\u00ban un estudio amplio.\n No existe tratamiento para el dengue, el cual ocasiona fiebre, dolor severo de articulaciones, dolor de cabeza y hemorragia.  Aproximadamente la mitad de la poblaci\u00c3\u00b3n mundial est\u00c3\u00a1 en riesgo de contraer la enfermedad transmitida por un mosquito, que infecta a cerca de 100 millones de personas cada a\u00c3\u00b1o, mayormente en Asia, \u00c3\u0081frica y Latinoam\u00c3\u00a9rica.\n Los resultados de una prueba inicial a la vacuna en 2012 encontraron que su eficacia era de 33% y que no proteg\u00c3\u00ada contra uno de los tipos de dengue.  Existen cuatro tipos distintos, y la vacuna fue creada para combatirlos todos.  En la prueba m\u00c3\u00a1s reciente, realizada en m\u00c3\u00a1s de 10.000 ni\u00c3\u00b1os de entre 2 y 14 a\u00c3\u00b1os en Indonesia, Malasia, Tailandia, Filipinas y Vietnam, la eficacia de la vacuna mejor\u00c3\u00b3 a 56%.  Las vacunas m\u00c3\u00a1s comunes, como la de sarampi\u00c3\u00b3n y poliomielitis, tienen una eficacia de m\u00c3\u00a1s de 95%.\n \"Todos nosotros hubi\u00c3\u00a9ramos deseado una mejor tasa de eficacia, pero esto es con lo que tenemos que vivir por el momento\", dijo Annelies Wilder-Smith, de la Universidad Tecnol\u00c3\u00b3gica de Nanyang en Singapur, quien escribi\u00c3\u00b3 un comentario para el estudio, el cual fue publicado el viernes en la revista Lancet.  \"Si la eficacia de esta vacuna es suficiente para que inviertan los pa\u00c3\u00adses, es una pregunta que deben responder los economistas\".\n Investigadores siguieron la pista a los ni\u00c3\u00b1os del estudio nuevo durante aproximadamente dos a\u00c3\u00b1os y notaron efectos secundarios como infecciones y lesiones.  El estudio fue pagado por Sanofi Pasteur, fabricante de la vacuna.\n Otros expertos dijeron que se requieren cifras de un seguimiento m\u00c3\u00a1s prolongado a ni\u00c3\u00b1os vacunados para valorar la seguridad de la vacuna.  La gente infectada con un tipo de dengue desarrolla anticuerpos que protegen contra nuevas infecciones de ese tipo; pero si se infectan con otro tipo de dengue, sus anticuerpos los hacen susceptibles a una enfermedad m\u00c3\u00a1s grave que podr\u00c3\u00ada incluir hemorragia.  A algunos cient\u00c3\u00adficos les preocupa que los anticuerpos de una vacuna contra el dengue pudieran tener el mismo efecto, y dijeron que los ni\u00c3\u00b1os vacunados deber\u00c3\u00adan ser monitoreados durante varios a\u00c3\u00b1os.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14904994",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.731,
                    "source": {
                        "title": "Frontera.info",
                        "uri": "www.frontera.info"
                    },
                    "time": "19:49:00",
                    "title": "Vacuna contra dengue ofrece algo de protecci\u00f3n",
                    "uri": "196421085",
                    "url": "http://www.frontera.info/EdicionEnlinea/Notas/CienciayTecnologia/10072014/862427-Vacuna-contra-dengue-ofrece-algo-de-proteccion.html",
                    "wgt": 1
                },
                {
                    "body": "Descubren frascos con virus de viruelaSeis probetas abandonadas con el virus de la viruela fueron descubiertas en un viejo laboratorio cerca de Washington D.C.\nEl dengue causa fiebre, dolor en las articulaciones, dolores de cabeza y sangrado.\n Alrededor de la mitad de la poblaci\u00f3n del mundo est\u00e1 en riesgo de la enfermedad que es transmitida por mosquitos y enferma a unas 100 millones de personas cada a\u00f1o, principalmente en Asia, \u00c1frica y Am\u00e9rica Latina, seg\u00fan la Organizaci\u00f3n Mundial de la Salud, y algunos expertos estiman que la cifra es tres veces m\u00e1s grande.\n En pruebas avanzadas que se llevaron a cabo en m\u00e1s de 10.000 ni\u00f1os de 2 a 14 a\u00f1os en Asia, la eficacia de la vacuna mejor\u00f3 a un 56 por ciento.  Vacunas comunes como las de sarampi\u00f3n y la poliomielitis poseen m\u00e1s de 95 por ciento de efectividad.\n Resultados de los estudios liderados por, Mar\u00eda Rosario Capeding, del Instituto de Investigaci\u00f3n par Medicina Tropical en Las Filipinas, sugieren que la vacuna act\u00faa como un estimulador inmunol\u00f3gico para pacientes con exposici\u00f3n previa, por lo tanto, siendo m\u00e1s \u00fatil en las regiones tropicales donde el dengue es com\u00fan.\n \"Considerando la elevada carga sanitaria en pa\u00edses en que el dengue es end\u00e9mico, esta posible vacuna, a pesar de tener una eficiencia general moderada, podr\u00eda tener un efecto sustancial en la salud p\u00fablica\", escribieron los cient\u00edficos del estudio.\n La mayor\u00eda de los pacientes sobreviven al dengue, pero la enfermedad mata a un total de 20.000 personas cada a\u00f1o, muchos de los cuales son ni\u00f1os.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14868935",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.6554,
                    "source": {
                        "title": "Voz de Am\u00e9rica",
                        "uri": "www.voanoticias.com"
                    },
                    "time": "16:37:00",
                    "title": "Vacuna contra el dengue es eficaz",
                    "uri": "196368315",
                    "url": "http://www.voanoticias.com/content/mosquitos-dengue-enfermedad/1955581.html",
                    "wgt": 1
                },
                {
                    "body": "La vacuna llamada CYD-TDV es producida por el laboratorio franc\u00e9s Sanofi Pasteur y es la primera en llegar a fase final de investigaci\u00f3n y elaboraci\u00f3n con resultados bastante alentadores.\n Los resultados indican la eficacia de un 75 por ciento en los tipos 2 y 3 de la enfermedad, mientras que para el tipo 4 hay un 50 por ciento y para el tipo 1 35 por ciento.  El dengue afecta a m\u00e1s de 390 millones de personas en todo el mundo, seg\u00fan dijo a EFE la directora m\u00e9dica para Latinoam\u00e9rica del laboratorio Sanofi Pasteur, Sandra Besada-Lombana.\n Por otra parte, Annelies Wilder-Smith, de la Universidad Tecnol\u00f3gica de Singapur, que dirigi\u00f3 una etapa anterior de la vacuna, mencion\u00f3 que una eficacia del 56 por ciento no es una soluci\u00f3n para el control del dengue pero es lo mejor a lo que el mundo puede acceder en estos tiempos.\n La \u00faltima fase del estudi\u00f3 alcanz\u00f3 a 10.275 ni\u00f1os de 2 a 14 a\u00f1os, residentes en Asia, espec\u00edficamente en Indonesia, Filipinas, Tailandia y Vietnam.  Todos ellos fueron beneficiados con una dosis cada seis meses durante un periodo de control de dos a\u00f1os.",
                    "date": "2014-07-11",
                    "eventUri": "970955",
                    "id": "14895119",
                    "isDuplicate": false,
                    "lang": "spa",
                    "sim": 0.5902,
                    "source": {
                        "title": "www.paraguay.com",
                        "uri": "www.paraguay.com"
                    },
                    "time": "19:03:00",
                    "title": "Vacuna contra dengue 56 por ciento efectiva",
                    "uri": "196409858",
                    "url": "http://www.paraguay.com/salud-y-educacion/vacuna-contra-dengue-56-por-ciento-efectiva-111770",
                    "wgt": 1
                }
            ]
        },
        "info": {
            "articleCount": 10,
            "averageDate": "2014-07-11",
            "avgCos": 0.5577,
            "categories": [],
            "customDate": false,
            "customLocation": false,
            "eventUri": "970955",
            "extractedDate": "",
            "extractedDateEnd": "",
            "id": "624417",
            "lang": "spa",
            "storyDate": "2014-07-11",
            "storyDateEnd": "",
            "uri": "e7e700df-6a06-44ea-a4f3-f736278fc36b-143568",
            "variance": 0.1889
        }
    },
    "meta": {
        "CCAArticleMatchCount": 67,
        "CCAArticleMatchRatio": 0.2838983050847458,
        "CCAAvgCosSim": 0.7373432835820897,
        "CCAAvgMatchWgt": 64.35820895522389,
        "_articleUri1": "196188235",
        "_articleUri2": "196351426",
        "_datetime": "2015-02-19 11:46:45",
        "_ruleBasedShouldMerge": true,
        "_storyUri1": "850f305d-14db-4c75-b547-79470a557ea3-553531",
        "_storyUri2": "e7e700df-6a06-44ea-a4f3-f736278fc36b-143568",
        "_username": "Evgenia Belyaeva",
        "artCount1": 20,
        "artCount2": 10,
        "avgCosSimStory1": 0.6196,
        "avgCosSimStory2": 0.5577,
        "categorySim": 0,
        "conceptCosSim": 0.6624426449838979,
        "conceptJaccardSim": 0.2894736842105263,
        "coreTime1": 127325.05,
        "coreTime2": 127326.5333333333,
        "coreTimeStDev1": 4.800276571712915,
        "coreTimeStDev2": 4.796156863542537,
        "entityCosSim": 0.6990199674437013,
        "entityJaccardSim": 0.4444444444444444,
        "extractedDateJaccardSim": 0,
        "extractedDatesStory1": 4,
        "extractedDatesStory2": 0,
        "hasSameLocation": 1,
        "keywordCosSim": 0.6578405869450514,
        "keywordJaccardSim": 0.2040816326530612,
        "lang1": "eng",
        "lang2": "spa",
        "matchingDateCount": 0,
        "matchingDateRatio": 0,
        "ratioAnnotatedArticlesStory1": 1,
        "ratioAnnotatedArticlesStory2": 1,
        "shouldMerge": true,
        "storyQuality1": 18,
        "storyQuality2": 15,
        "timeAvg1": 127334.135,
        "timeAvg2": 127332.2033333333,
        "timeStDev1": 8.758021561213903,
        "timeStDev2": 5.240312755719358,
        "varianceStory1": 0.4661,
        "varianceStory2": 0.1889
    }
}